blood cancer Archives
Research identifies new target that may prevent blood cancer
Apr. 12, 2023—An international coalition of biomedical researchers co-led by Vanderbilt's Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.
VUMC researcher selected for Global Scholars Program
Mar. 30, 2023—Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.
Researchers clarify role of blood cell mutations in disease
Feb. 2, 2023—Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.
Blood cancer progression
Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
Computer eyeballs graft-vs-host disease
Apr. 7, 2022—A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.
Study finds 10-second videos predict blood cancer relapse
Mar. 28, 2022—Vanderbilt research shows that 10-second videos of white blood cell motion in the skin’s microvasculature greatly improved the prediction of which stem cell and bone marrow transplant patients would have a relapse of their blood cancer.
Study finds World Trade Center responders at higher risk for blood cancer-associated mutations
Mar. 7, 2022—A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease
Convalescent plasma improved survival in COVID-19 patients with blood cancers
Feb. 5, 2021—Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
